Pharma Industry News

Sanofi sees double-digit growth driven by ‘megabrand’ Dupixent

With strong growth in specialty care, vaccines and consumer health seeing sales rise by 10% in the third quarter, Sanofi now expects earnings to grow by 14% in 2021

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]